Obsessive Compulsive Disorder Market Size in the 7MM was ~USD 11,00 Million in 2023 and it is projected to grow at a significant CAGR by 2034

DelveInsight's "Obsessive Compulsive Disorder Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of the Sarcoidosis, historical and forecasted epidemiology as well as the Obsessive Compulsive Disorder market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Unlock detailed insights into the Obsessive Compulsive Disorder Market by downloading the comprehensive report from DelveInsight @ Obsessive Compulsive Disorder Therapeutics Market

Key Takeaways from the Obsessive Compulsive Disorder Market Report

• In February, 2026, Yale University announced a trial aims to evaluate the efficacy, safety and tolerability of valbenazine, titrated to the subject's optimal dose of 40mg or 80mg, administered once daily, for 12 weeks, for the treatment of trichotillomania (TTM) in a double blind placebo controlled design study. After week 12, subjects will begin a 12-week, open-label portion of the study. During the open-label portion of the study, all subjects will receive the study drug at their optimal dose. The primary endpoint of these studies will be the change from baseline of placebo vs. active scores utilizing the Massachusetts General Hospital Hairpulling Scale (MGH-HPS) at the end of Week 12.
• In 2023, the total prevalent cases of OCD were ~12,125 thousand cases in the 7MM. These cases are expected to increase by 2034.
• In 2023, the total diagnosed cases of OCD were ~7,299 thousand cases in 7MM. These cases are expected to increase by the year 2034.
• Among the EU4 countries and the UK, the highest number of diagnosed cases of OCD were found in Germany, i.e., ~1,305 thousand cases in the year 2023, which are estimated to increase by the year 2034.
• In 2023, total diagnosed prevalent cases in Japan were ~1,168 thousand cases of OCD, which was approximately 16% of the total OCD cases in 7MM.
• In 2023, US accounted for ~319 thousand cases of mild OCD whereas, ~1,106 thousand cases of severe OCD were observed for the severity-specific cases of OCD.
• In 2023, Germany accounted for ~191 thousand cases of mild OCD and ~660 thousand cases of severe OCD were observed for the severity-specific cases of OCD.
• In 2023, the least number of age-specific diagnosed prevalent cases of OCD were observed in the age group, 60 and above, whereas the 30-44 years age group accounted for the highest number of cases of OCD in France.
• In the UK, out of the total prevalent cases, ~101 thousand cases and ~360 thousand cases of OCD were found in males and females, respectively in 2023. These cases are expected to increase by 2034.
• The leading Obsessive Compulsive Disorder Companies such as Biohaven Pharmaceutical Holding Company Ltd., Alkermes plc, Intra-Cellular Therapies, Inc., Takeda Pharmaceutical Company Limited, Johnson & Johnson, Mylan N.V., Cipla Limited, Eli Lilly and Company, Pfizer Inc., Bristol-Myers Squibb Company, GlaxoSmithKline plc, Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd., H. Lundbeck A/S, Neurocrine Biosciences Inc., Impel NeuroPharma, Janssen Pharmaceuticals, Inc. (a subsidiary of Johnson & Johnson), Novartis International AG, Sun Pharmaceutical Industries Ltd., Allergan plc (now part of AbbVie Inc.), and others.
• Promising Obsessive Compulsive Disorder Therapies such as ZOLOFT, Troriluzole, and others.

Gain a competitive edge in the Obsessive Compulsive Disorder Market by exploring our in-depth analysis @ Obsessive Compulsive Disorder Treatment Drugs

Obsessive Compulsive Disorder Epidemiology Segmentation in the 7MM

• Total Obsessive Compulsive Disorder Prevalent Cases
• Total Obsessive Compulsive Disorder Diagnosed Cases
• Obsessive Compulsive Disorder Severity-specific Cases
• Obsessive Compulsive Disorder Gender-specific Cases
• Obsessive Compulsive Disorder Age-specific Cases

Obsessive Compulsive Disorder Treatment Market

Obsessive Compulsive Disorder treatment comprises several components, starting with building a therapeutic alliance with the patient and psychoeducation. Then psychological and/or pharmacological approaches, and, for patients with treatment-resistant OCD, neuromodulation and neurosurgery. Alternative interventions have also attracted interest but require more evidence. Although general principles of management exist, they need to be individually tailored.

Discover key developments and opportunities in the Obsessive Compulsive Disorder Market @ Obsessive Compulsive Disorder Market Size

Obsessive Compulsive Disorder Emerging Drugs Profile

• Troriluzole: Biohaven Pharmaceuticals

Troriluzole is a new chemical entity ("NCE") and tripeptide prodrug of the active metabolite, riluzole. Troriluzole is optimized for improved bioavailability, pharmacokinetics, tolerability, and dosing compared to its active metabolite. Based on its mechanism of action, preclinical data, and clinical studies, troriluzole has the potential for therapeutic benefit in neurological and neuropsychiatric illnesses.

Obsessive Compulsive Disorder Market Outlook

OCD can be treated using pharmacotherapy, specialized psychotherapy, anatomically targeted treatments, or their combination. First-line treatments include cognitive-behavioral therapy and pharmacotherapy with the selective serotonin reuptake inhibitors (SSRIs). In this article we review evidence-based pharmacotherapies for OCD, as well as alternatives that may be considered in refractory patients. Other treatment modalities are reviewed in other articles in this issue.

Download DelveInsight's Obsessive Compulsive Disorder Market report today and stay ahead in this rapidly evolving field. @ Obsessive Compulsive Disorder Clinical Trials

Scope of the Obsessive Compulsive Disorder Market Report

• Coverage- 7MM
• Study Period- 2020-2034
• Obsessive Compulsive Disorder Companies- Biohaven Pharmaceutical Holding Company Ltd., Alkermes plc, Intra-Cellular Therapies, Inc., Takeda Pharmaceutical Company Limited, Johnson & Johnson, Mylan N.V., Cipla Limited, Eli Lilly and Company, Pfizer Inc., Bristol-Myers Squibb Company, GlaxoSmithKline plc, Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd., H. Lundbeck A/S, Neurocrine Biosciences Inc., Impel NeuroPharma, Janssen Pharmaceuticals, Inc. (a subsidiary of Johnson & Johnson), Novartis International AG, Sun Pharmaceutical Industries Ltd., Allergan plc (now part of AbbVie Inc.), and others.
• Obsessive Compulsive Disorder Therapies- ZOLOFT, Troriluzole, and others.
• Obsessive Compulsive Disorder Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
• Obsessive Compulsive Disorder Unmet Needs, KOL's views, Analyst's views, Obsessive Compulsive Disorder Market Access and Reimbursement

Download the report to understand which factors are driving Obsessive Compulsive Disorder Market Trends @ Obsessive Compulsive Disorder Market Trends

Table of Content

1. Key Insights

2. Obsessive Compulsive Disorder Market Report Introduction

3. Obsessive Compulsive Disorder Market Overview at a Glance

4. Executive Summary of Obsessive-compulsive Disorder

5. Epidemiology and Market Methodology

6. Disease Background and Overview

7. Obsessive Compulsive Disorder Epidemiology and Patient Population

8. Patient Journey

9. Obsessive Compulsive Disorder Marketed Therapies

10. Obsessive Compulsive Disorder Emerging Therapies

11. Obsessive Compulsive Disorder: The 7MM Market Analysis

12. KOL Views

13. SWOT Analysis

14. Obsessive Compulsive Disorder Unmet needs

15. Obsessive Compulsive Disorder Market Access and Reimbursement

16. Appendix

17. DelveInsight Capabilities

18. Disclaimer

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.